Bone marrow iron score as an indicator for secondary iron overload in acute myeloid leukemia patients

European Journal of Haematology
Marlijn HoeksJaap Jan Zwaginga

Abstract

Secondary iron overload due to red blood cell transfusions (RBCT) is associated with increased morbidity and mortality. However, attention for secondary iron overload and its side effects in patients with hematological malignancies may need improvement. The aim of this study was to determine the number of transfused RBCT needed to reach a maximum bone marrow iron score (BMIS). Bone marrow iron score was independently assessed by two researchers on consecutive bone marrow samples of 35 acute myeloid leukemia (AML) patients. The slides were blinded to both researchers to prevent bias. A Kaplan-Meier survival analysis was performed for estimation of the proportion of patients reaching a maximum BMIS. In total, 141 bone marrow specimens from 35 patients were included. The median number of RBCT to reach a maximum was 20 units (range 6-42, IQR 15-26), after a mean of 1.64 chemotherapy courses (SD 0.99). In conclusion, the cumulative RBCT number is associated with BMIS. Due to the considerable variation in number of RBCT to reach a maximum BMIS, BMIS instead of only considering the cumulative RBCT number may be a valuable indicator of secondary iron overload in AML patients. BMIS could guide iron-lowering therapy and/or transfusion st...Continue Reading

References

Aug 26, 1998·Bone Marrow Transplantation·S I StrasserG B McDonald
Sep 22, 2010·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Philippe ArmandJoseph H Antin
Oct 13, 2010·Annals of Hematology·Norbert Gattermann, Eliezer A Rachmilewitz
Jan 15, 2011·Journal of the National Comprehensive Cancer Network : JNCCN·Peter L GreenbergUNKNOWN National Comprehensive Cancer Network
Sep 19, 2012·Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis·Serdar SivginAli Unal
Dec 10, 2013·Hematology·John Porter, Maciej Garbowski
Jun 8, 2017·British Journal of Haematology·Marlijn P A HoeksJaap-Jan Zwaginga

❮ Previous
Next ❯

Citations

Jul 31, 2020·The Kaohsiung Journal of Medical Sciences·Xue-Qiong WuTing Yang
Nov 23, 2019·Blood Reviews·Eolia BrissotMarie-Bérengère Troadec

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

© 2022 Meta ULC. All rights reserved